| Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy B Werle–Lapostolle, S Bowden, S Locarnini, K Wursthorn, J Petersen, ... Gastroenterology 126 (7), 1750-1758, 2004 | 1193 | 2004 |
| Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil C Westland, W Delaney IV, H Yang, S Chen, P Marcellin, S Hadziyannis, ... Gastroenterology 125 (1), 107-116, 2003 | 375 | 2003 |
| The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro WE Delaney IV, H Yang, CE Westland, K Das, E Arnold, CS Gibbs, ... Journal of virology 77 (21), 11833-11841, 2003 | 355 | 2003 |
| Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus WE Delaney IV, AS Ray, H Yang, X Qi, S Xiong, Y Zhu, MD Miller Antimicrobial agents and chemotherapy 50 (7), 2471-2477, 2006 | 322 | 2006 |
| Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks H Yang, CE Westland, WED IV, EJ Heathcote, V Ho, J Fry, C Brosgart, ... Hepatology 36 (2), 464-473, 2002 | 235 | 2002 |
| Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B CE Westland, H Yang, WE Delaney IV, CS Gibbs, MD Miller, M Wulfsohn, ... Hepatology 38 (1), 96-103, 2003 | 233 | 2003 |
| Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV H Yang, X Qi, A Sabogal, M Miller, S Xiong, WE Delaney IV Antiviral therapy 10 (5), 625-633, 2005 | 231 | 2005 |
| In Vitro Susceptibility of Adefovir-Associated Hepatitis B Virus Polymerase Mutations to other Antiviral Agents X Qi, S Xiong, H Yang, M Miller, WE Delaney IV Antiviral therapy 12 (3), 355-362, 2007 | 223 | 2007 |
| Activity of adefovir dipivoxil against all patterns of lamivudine‐resistant hepatitis B viruses in patients CE Westland, H Yang, WE Delaney IV, M Wulfsohn, N Lama, CS Gibbs, ... Journal of viral hepatitis 12 (1), 67-73, 2005 | 191 | 2005 |
| Phenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitro WE Delaney IV, R Edwards, D Colledge, T Shaw, P Furman, G Painter, ... Antimicrobial agents and chemotherapy 46 (9), 3057-3060, 2002 | 180 | 2002 |
| Resistance of hepatitis B virus to antiviral drugs: current aspects and directions for future investigation WE Delaney IV, S Locarnini, T Shaw Antiviral Chemistry and Chemotherapy 12 (1), 1-35, 2001 | 177 | 2001 |
| Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine‐resistant HBV in vitro RYM Chen, R Edwards, T Shaw, D Colledge, WE Delaney IV, H Isom, ... Hepatology 37 (1), 27-35, 2003 | 164 | 2003 |
| Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus WE Delaney IV, R Edwards, D Colledge, T Shaw, J Torresi, TG Miller, ... Antimicrobial agents and chemotherapy 45 (6), 1705-1713, 2001 | 156 | 2001 |
| The Smc5/6 complex restricts HBV when localized to ND10 without inducing an innate immune response and is counteracted by the HBV X protein shortly after infection C Niu, CM Livingston, L Li, RK Beran, S Daffis, D Ramakrishnan, ... PloS one 12 (1), e0169648, 2017 | 142 | 2017 |
| Combinations of adefovir with nucleoside analogs produce additive antiviral effects against hepatitis B virus in vitro WE Delaney IV, H Yang, MD Miller, CS Gibbs, S Xiong Antimicrobial agents and chemotherapy 48 (10), 3702-3710, 2004 | 125 | 2004 |
| In vitro antiviral susceptibility of full-length clinical hepatitis B virus isolates cloned with a novel expression vector H Yang, C Westland, S Xiong, WE Delaney IV Antiviral research 61 (1), 27-36, 2004 | 109 | 2004 |
| Inhibitory effect of adefovir and lamivudine on the initiation of hepatitis B virus infection in primary tupaia hepatocytes J Köck, TF Baumert, WED IV, HE Blum, F von Weizsäcker Hepatology 38 (6), 1410-1418, 2003 | 109 | 2003 |
| Use of the hepatitis B virus recombinant baculovirus-HepG2 system to study the effects of (−)-β-2′, 3′-dideoxy-3′-thiacytidine on replication of hepatitis B virus and … WE Delaney IV, TG Miller, HC Isom Antimicrobial agents and chemotherapy 43 (8), 2017-2026, 1999 | 101 | 1999 |
| Toll-like receptor 7 agonist GS-9620 induces prolonged inhibition of HBV via a type I interferon-dependent mechanism C Niu, LI Li, S Daffis, J Lucifora, M Bonnin, S Maadadi, E Salas, R Chu, ... Journal of hepatology 68 (5), 922-931, 2018 | 99 | 2018 |
| Genome‐free hepatitis B virion levels in patient sera as a potential marker to monitor response to antiviral therapy L Luckenbaugh, KM Kitrinos, WE Delaney Iv, J Hu Journal of viral hepatitis 22 (6), 561-570, 2015 | 88 | 2015 |
